Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 5.15%
As of Friday, August 28, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. COAG
$44.37
-0.33
-0.74%
September 3, 2026 4:00:00 PM
EST
Volume: 257,208
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 7.18%
As of Friday, August 21, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 7.18%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 6.06%
As of Friday, August 07, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 6.49%
As of Tuesday, August 04, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 6.49%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 6.51%
As of Wednesday, July 29, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 6.51%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | COAG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,088.0 | $288.9 | 54% |
|
| Shares Out (Mil) | 30.1 | 54.0 | 37% |
|
| Institutional Ownership | 99.4% | 93.1% | 88% |
|
| Float (Mil) | 20.3 | 41.4 | 29% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 387 | 480 | 55% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.510) | ($3.100) | ($2.538) | |
| Month Ago EPS | ($0.487) | ($3.063) | ($2.513) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.460) | ($3.035) | ($2.325) | |
| Year/Year Chg | (36.4%) | (95.4%) | (95.2%) | |
| Financials | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($83) | ($43) | 12% |
|
| EPS (TTM) | ($10.055) | ($1.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $137 | $2 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $1,957 | $190 | 48% |
|
| Valuation | COAG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.59 | 2.84 | 76% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | COAG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (35.6%) | (47.7%) | 15% |
|
| ROE | (36.6%) | (55.0%) | 18% |
|
| Liabilities to Assets | 2.9% | 29.6% | 1% |
|
| F-Score | 1 | 3 | na |
|
Hemab Therapeutics Holdings, Inc. did not pass any screens on 9/2/2026.
